Identification of two molecular subtypes of dysregulated immune lncRNAs in ovarian cancer
Identification of two molecular subtypes of dysregulated immune lncRNAs in ovarian cancer
复制标题
DOI：
10.1177/1535370220972024
复制
发表时间：
2021-03-01
影响因子：
3.2
通讯作者：
Jin, Zhijun
中科院分区：
文献类型：
--
作者：
Liu, Xiaojun;Gao, Jinghai;Jin, Zhijun
长链非编码RNA（lncRNA）已越来越多地被确定为病理学（如癌症）的关键调节因子。使用多个平台对卵巢癌进行综合分析，以确定分子亚组。然而，lncRNA及其在定位卵巢癌亚群中的作用在很大程度上仍然是未知的。从癌症基因组图谱数据库（TCGA）获得卵巢癌的RNA测序和临床特征。共鉴定出52种特异于卵巢癌的异常免疫lncRNA。我们在“iClinterPlus”R软件包中重新定义了两种不同的分子亚型C1（188例）和C2（184例），其中C2分组的卵巢癌样本具有较高的生存概率和较长的中位生存时间（P
Long non-coding RNA (lncRNA) has increasingly been identified as a key regulator in pathologies such as cancer. Multiple platforms were used for comprehensive analysis of ovarian cancer to identify molecular subgroups. However, lncRNA and its role in mapping the ovarian cancer subpopulation are still largely unknown. RNA-sequencing and clinical characteristics of ovarian cancer were acquired from The Cancer Genome Atlas database (TCGA). A total of 52 lncRNAs were identified as aberrant immune lncRNAs specific to ovarian cancer. We redefined two different molecular subtypes, C1(188) and C2(184 samples), in "iClusterPlus" R package, among which C2 grouped ovarian cancer samples have higher survival probability and longer median survival time (P